Page 783 - Clinical Immunology_ Principles and Practice ( PDFDrive )

754 Part SIX Systemic Immune Diseases

TABLE 55.6 Differential Diagnosis of REFERENCES
Systemic Sclerosis (SSc) and Scleroderma
1. Maricq HR, Weinrich MC, Keil JE, et al. Prevalence of scleroderma
Disorders Characterized by Similar Presentations spectrum disorders in the general population of South Carolina. Arthritis
• Systemic lupus erythematosus Rheum 1989;32:998–1006.
• Sjögren syndrome 2. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence,
• Rheumatoid arthritis survival, and disease characteristics of systemic sclerosis in a large US
• Polymyositis/dermatomyositis population. Arthritis Rheum 2003;48:2246–55.
• Primary Raynaud phenomenon 3. Bossini-Castillo L, López-Isac E, Martín J. Immunogenetics of systemic
sclerosis: defining heritability, functional variants and
Disorders Characterized by Similar Visceral Features shared-autoimmunity pathways. J Autoimmun 2015;64:53–65.
• Primary pulmonary hypertension 4. Hummers LK. The importance of recognizing scleroderma-type disorders
• Primary biliary cirrhosis in clinical practice. Nat Clin Pract Rheumatol 2008;4:638–40.
• Idiopathic intestinal hypomotility 5. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation
• Idiopathic pulmonary fibrosis between silicone breast implants and the risk of connective-tissue
• Malignant hypertension diseases. N Engl J Med 2000;342:781–90.
6. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic
Disorders Characterized by Skin thickening sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol
• Scleromyxedema 2011;8:42–54.
• Scleredema (of Buschke), diabetic scleredema 7. Kuwana M, Okazaki Y, Yasuoka H, et al. Defective vasculogenesis in
• Nephrogenic fibrosing dermatopathy systemic sclerosis. Lancet 2004;364:603–10.
• Eosinophilic fasciitis/diffuse fasciitis with eosinophilia 8. Sato S, Fujimoto M, Hasegawa M, et al. Altered blood B lymphocyte
• Eosinophilia–myalgia syndrome homeostasis in systemic sclerosis: expanded naive B cells and diminished
• Generalized morphea but activated memory B cells. Arthritis Rheum 2004;50:1918–27.
• Chronic graft versus host disease 9. Harris ML, Rosen A. Autoimmunity in scleroderma: the origin,
• POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy,
monoclonal protein, skin changes) pathogenetic role, and clinical significance of autoantibodies. Curr Opin
• Amyloidosis Rheumatol 2003;15:778–84.
• Carcinoid syndrome 10. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular
• Pentazocine-induced scleroderma SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum
• Diabetic digital sclerosis 2003;48:1964–78.
• Vinyl chloride disease 11. Domsic RT, Rodriguez-Reyna T, Lucas M, et al. Skin thickness
• Toxic oil syndrome progression rate: a predictor of mortality and early internal organ
• Bleomycin exposure involvement in diffuse scleroderma. Ann Rheum Dis 2011;70:104–9.
• Werner syndrome 12. Mendoza F, Derk CT. Systemic sclerosis mortality in the United States:
• Phenylketonuria 1999-2002 implications for patient care. J Clin Rheumatol
• Porphyria cutanea tarda 2007;13:187–92.
• Vibration white finger syndrome 13. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic
• Chronic reflex sympathetic dystrophy sclerosis. J Rheumatol 2001;28:1573–6.
14. Chung L, Domsic RT, Lingala B, et al. Survival and predictors of
mortality in systemic sclerosis-associated pulmonary arterial
hypertension: outcomes from the pulmonary hypertension assessment
and recognition of outcomes in scleroderma registry. Arthritis Care Res
2014;66:489–95.
histological evidence of an inflammatory process in the fasciae 15. Flavahan NA. A vascular mechanistic approach to understanding
is present. Nephrogenic systemic fibrosis is described in patients Raynaud phenomenon. Nature 2015;11:146–58.
with end-stage renal disease who were exposed to gadolinium- 16. Cappelli L, Wigley FM. Management of Raynaud phenomenon and
35
based contrast agents. Scleromyxedema, a condition of mucinous digital ulcers in scleroderma. Rheum Dis Clin North Am 2015;41:
deposition in skin, is associated with the presence of monoclonal 419–38.
gammopathy that is characterized by a diffuse, papular skin 17. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic
eruption. Scleredema occurs with deposition of collagen and sclerosis: prevention by treatment with bosentan, an oral endothelin
receptor antagonist. Arthritis Rheum 2004;50:3985–93.
mucin in the dermis and primarily involves the upper back, 18. Roberts CG, Hummers LK, Ravich WJ, et al. A case-controlled study of
neck, and face. It occurs in association with diabetes, a monoclonal the pathology of oesophageal disease in systemic sclerosis (scleroderma).
gammopathy, or postinfection pharyngitis, particularly streptococ- Gut 2006;55:1697–703.
cal pharyngitis. GvHD occurs after bone marrow or stem cell 19. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in
transplantation and is characterized by patchy areas of inflam- systemic sclerosis: a study from the EULAR Scleroderma Trials and
matory and thickened skin with liver and GI involvement. Toxin Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809–15.
exposure was linked to the toxic oil syndrome (adulterated 20. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in
rapeseed oil) and eosinophilia–myalgia syndrome (related to systemic sclerosis: a simple staging system. Am J Respir Crit Care Med
the presence of an impurity in the production process for 2008;177:1248–54.
L-tryptophan, a sleep aid). These syndromes have largely subsided 21. Tashkin DP, Elashoff R, Clements PJ, et al. Scleroderma Lung Study
by banning the agents involved, but sporadic cases of eosinophilia– Research Group. Cyclophosphamide versus placebo in scleroderma lung
disease. N Engl J Med 2006;354:2655–66.
myalgia syndrome continue to occur. 36 22. Clements PJ, Tashkin D, Roth M, et al. The Scleroderma Lung Study II
(SLS II) shows that both oral cyclophosphamide (CYC) and
Please check your eBook at https://expertconsult.inkling.com/ mycophenolate mofetil (MMF) are efficacious in treating progressive
for self-assessment questions. See inside cover for registration interstitial lung disease (ILD) in patients with systemic sclerosis (SSc).
details. Arthritis Rheumatol 2015;67(Suppl. 10). http://acrabstracts.org/abstract/